Regenerative Therapy
Clinical Guide to Stem Cells & Regenerative Medicine
“Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis.”
Clin Pharmacol Ther. 2010 Jun;87(6):679-85
Rice CM et al.
SourceInstitute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, UK.
“In this phase I study, we assessed the safety and feasibility of intravenous, autologous bone marrow (BM) cell therapy, without immunosuppressive preconditioning, in six patients with clinically definite, relapsing-progressive multiple sclerosis (MS)”
“The lack of serious adverse effects and the suggestion of a beneficial effect in this …
American Cryostem
The Company’s provides processing and cryopreservation of Adipose Derived Stem Cells and Adipose Tissue for autologous use.
American CryoStem Corporation
Red Bank, NJ USA
http://www.americancryostem.com/
BrainStorm Announces Clinical Data Supporting Safety and Efficacy of NurOwn™ Based on Initial ALS Patient Results
The ALS Phase I/II human clinical trial is being performed at Hadassah Medical Center in Israel in collaboration with BrainStorm and is utilizing BrainStorm’s NurOwn™ technology for growing and modifying autologous adult human stem cells to treat ALS, often referred to as Lou Gehrig’s Disease. The study is headed by Prof. Karussis, M.D., Ph.D
http://www.brainstorm-cell.com/Index.asp?ArticleID=260&CategoryID=76&Page=1
New clinical study to treat hearing loss by cord blood stem cells has been approved by the FDA:
“Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children”
Acquired sensorineural hearing loss i children will be treated with autologous cord blood cells. The primary objective of this study is to determine the safety of autologous hUCB infusion in children with acquired hearing loss. The secondary objective is to determine if functional, physiologic and anatomic outcomes …
Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells
Yong Zhao, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, Ye Zhang, Yalin Diao, Yunxiang Li, Yingjian Chen, Xiaoming Sun, Mary Beth Fisk, Randal Skidgel, Mark Holterman, Bellur Prabhakar and Theodore Mazzon
BMC Medicine 2012, 10:3 http://www.biomedcentral.com/1741-7015/10/3/abstract
“A procedure for Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop system that separate lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them …
Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.
Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, Kawa K, Koike K, Tauchi H, Kajiwara M, Hara T, Kato S; Japanese Cord Blood Bank Network.
Department of Paediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan.
“Umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between …
